Fineline Cube

Follow:
14686 Articles
Sansure Biotech's Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens
CompanyMedical Device

Sansure Biotech’s Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Guangdong True Health Medical's Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World's First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model
Company

Guangdong True Health Medical’s Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World’s First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors
CompanyDrug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis
CompanyR&D

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure
CompanyMedical Device

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

CompanyDrug

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

BrightGene's BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes
CompanyDrug

BrightGene’s BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes

Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach
CompanyMedical Device

Beijing Balance Medical’s Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach

Chipscreen Biosciences' CS43158 Wins NMPA Clinical Trial Approval – Multi‑Target Kinase Inhibitor Aims to Overcome FLT3 Resistance in Acute Myeloid Leukemia
CompanyDrug

Chipscreen Biosciences’ CS43158 Wins NMPA Clinical Trial Approval – Multi‑Target Kinase Inhibitor Aims to Overcome FLT3 Resistance in Acute Myeloid Leukemia

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

BMS's RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs
CompanyDrug

BMS’s RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs